James Polewaczyk - IDEXX Laboratories Executive Officer
| IDXX Stock | USD 417.24 1.31 0.31% |
Executive
James Polewaczyk is Executive Officer of IDEXX Laboratories
| Age | 60 |
| Phone | 207 556 0300 |
| Web | https://www.idexx.com |
James Polewaczyk Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Polewaczyk against IDEXX Laboratories stock is an integral part of due diligence when investing in IDEXX Laboratories. James Polewaczyk insider activity provides valuable insight into whether IDEXX Laboratories is net buyers or sellers over its current business cycle. Note, IDEXX Laboratories insiders must abide by specific rules, including filing SEC forms every time they buy or sell IDEXX Laboratories'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Polewaczyk over three months ago Disposition of 3290 shares by James Polewaczyk of IDEXX Laboratories at 558.8822 subject to Rule 16b-3 | ||
James Polewaczyk over six months ago Disposition of 680 shares by James Polewaczyk of IDEXX Laboratories at 559.3318 subject to Rule 16b-3 |
IDEXX Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.2279 % which means that it generated a profit of $0.2279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5942 %, meaning that it created $0.5942 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Miriame Victor | Revvity | 42 | |
| Christian Magloth | Mettler Toledo International | 58 | |
| Todd Spencer | Charles River Laboratories | N/A | |
| John Kohl | Agilent Technologies | N/A | |
| Karen Nelson | Thermo Fisher Scientific | N/A | |
| Karl Guenault | IQVIA Holdings | N/A | |
| Scott Davies | Illumina | N/A | |
| Gary Curtis | ICON PLC | N/A | |
| Charles Esq | Illumina | 65 | |
| Jonathan Curtain | ICON PLC | 48 | |
| Chet Gandhi | Twist Bioscience Corp | N/A | |
| Marc Gueronniere | Mettler Toledo International | 60 | |
| Christos Ross | Waters | N/A | |
| Jim Berkshire | IQVIA Holdings | N/A | |
| Kristen Garvey | Waters | N/A | |
| Michael Fero | Twist Bioscience Corp | N/A | |
| Peter Aggersbjerg | Mettler Toledo International | 56 | |
| Gretchen Weightman | Illumina | N/A | |
| Jayashree Thacker | Revvity | N/A | |
| Sallilyn Schwartz | Illumina | N/A | |
| Jakob Wedel | Illumina | N/A | |
Management Performance
| Return On Equity | 0.59 | ||||
| Return On Asset | 0.23 |
IDEXX Laboratories Leadership Team
Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sharon JD, General VP | ||
| Nimrata PE, Sector Strategy | ||
| Martin Smith, Executive CTO | ||
| Michael Lane, Corporate Vice President General Manager | ||
| Jeffery Chadbourne, Director Reporting | ||
| George Fennell, Senior Officer | ||
| Sharon Underberg, Corporate Vice President General Counsel, and Corporate Secretary | ||
| Ken Grady, Senior Officer | ||
| Kerry Bennett, Senior Labs | ||
| Michael Johnson, Executive Officer | ||
| Jonathan Mazelsky, CEO President | ||
| James Polewaczyk, Executive Officer | ||
| John Hart, Senior Operations | ||
| Michael Erickson, Executive Telemedicine | ||
| Brian McKeon, CFO, Principal Accounting Officer, Executive VP and Treasurer |
IDEXX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IDEXX Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.59 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.37 % | ||||
| Current Valuation | 34.86 B | ||||
| Shares Outstanding | 81.88 M | ||||
| Shares Owned By Insiders | 0.94 % | ||||
| Shares Owned By Institutions | 94.24 % | ||||
| Number Of Shares Shorted | 2.08 M | ||||
| Price To Earning | 61.31 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.